INMED PHARMACEUTICALS INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
INMED PHARMACEUTICALS INC. (INM) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$4.71 million for the 12-month period ending 2022-06-30, per its 10-K filed 2022-09-23.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2022-09-23
- INMED PHARMACEUTICALS INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$4.71M.
- INMED PHARMACEUTICALS INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2021 was -$2.75M.
- INMED PHARMACEUTICALS INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2020 was -$2.41M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2022-06-30 | -$4.71M 10-K · filed 2022-09-23 |
| 2021-06-30 | -$2.75M 10-K · filed 2022-09-23 |
| 2020-06-30 | -$2.41M 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |